Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ: toxicity and cosmetic outcome from a prospective series.

CONCLUSION: Hypofractionated radiotherapy using VMAT is a viable option for DCIS. A longer follow up is needed to assess clinical outcomes and late toxicity. Advances in knowledge: The use of hypofractionated VMAT is dosimetrically feasible for treating breast DCIS.
PMID: 29322827 [PubMed - as supplied by publisher]

Source: The British Journal of Radiology - January 11, 2018 Category: Radiology Authors: De Rose F, Fogliata A, Franceschini D, Iftode C, Torrisi R, Masci G, Sagona A, Tinterri C, Testori A, Gatzemeier W, Fernandes B, Rahal D, Cozzi L, Santoro A, Scorsetti M Tags: Br J Radiol Source Type: research